PPD Recognized for Excellence in Clinical Research

04 May 2015


WILMINGTON, N.C., (May 4, 2015) – Pharmaceutical Product Development, LLC (PPD) today announced it has been recognized for excellence in clinical research by pharmaceutical and biotechnology company executives surveyed for Life Science Leader magazine’s 2015 CRO Leadership Awards.

PPD earned honors for high quality and reliability, based on survey responses from more than 2,300 industry executives responsible for making or influencing decisions to outsource clinical development programs to contract research organizations (CROs).

The company spans the value chain of clinical research with integrated Phase I-IV services and PPD® Laboratories, which offers the most comprehensive lab services available in the industry, from pharmaceutical discovery through late stage research.

“These awards recognize our talented professionals who are dedicated to providing innovative services that our clients can count on in their efforts to deliver life-changing therapies to patients more quickly and cost-effectively,” said Jay Dixon, senior vice president for global quality and compliance at PPD. “We share our clients’ passion for advancing medical research, and we are committed to collaboration, operational excellence and high-quality service delivery.”

The Life Science Leader CRO Leadership Awards are based on surveys and industry research conducted by Nice Insight, the market research division of That’s Nice LLC, to help the publication’s subscribers assess CROs.

About PPD

PPD is a leading global contract research organization providing drug discovery, development, lifecycle management and laboratory services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 46 countries and more than 13,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit


PPD Contacts

Elizabeth Humphrey
+1 910 558 6096


Nate Speicher
+1 910 558 6783

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD’s award-winning client services contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: competition in the outsourcing industry; PPD’s ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD’s estimates or views as of any date subsequent to the date hereof.

Contact Us

Media Contacts:

Randy Buckwalter Senior Manager, Corporate Communications
Tel: +1 919 456 4425

Holly Devine Manager, Corporate Communications
Tel: +1 919 456 6389

Contact Legal Notices Modern Slavery Transparency Statement Privacy Policy

© 2019 Pharmaceutical Product Development, LLC. All rights reserved.